SCHEMBL3691064

SCHEMBL3691064

CC(=O)Oc1ccc(Cl)cc1C(C)=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.61
MAPT P10636 3/20 0.54
CFD P00746 2/20 0.51
ABCB11 O95342 1/20 0.50
NR1H4 Q96RI1 1/20 0.49
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 4/20 0.46
TSHR P16473 2/20 0.46
HPGD P15428 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
ESR1 P03372 1/20 0.46
ITGB3 P05106 1/20 0.46
ITGA2B P08514 1/20 0.46
HMGB1 P09429 1/20 0.46
GGT1 P19440 1/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
BLM P54132 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239981 0.87 CFD (0.50) KMT2AMAPTCFDABCB11NR1H4
SCHEMBL329298 0.87 CFD (0.69) KMT2ACFDRAB9AALDH1A1KDM4E
SCHEMBL30472752 0.86 KDM4E (0.51) KMT2AMAPTCFDABCB11NR1H4
SCHEMBL7414042 0.84 ABL1 (0.54) KMT2AMAPTCFDABCB11NR1H4
SCHEMBL220769 0.84 KMT2A (0.57) KMT2AMAPTABCB11RAB9ANPC1
SCHEMBL364764 0.83 ALDH1A1 (0.65) KMT2AMAPTRAB9ANPC1ALDH1A1
SCHEMBL12513723 0.83 KMT2A (0.56) KMT2AMAPTNR1H4RAB9ANPC1
SCHEMBL11338058 0.82 KDM4E (0.58) KMT2AMAPTCFDABCB11NR1H4
SCHEMBL134715 0.81 KMT2A (0.57) KMT2AMAPTCFDABCB11NR1H4
SCHEMBL7803837 0.80 KMT2A (0.47) KMT2AMAPTCFDABCB11NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed
EP-1597248-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-11-23 EP disclosed
WO-2004073606-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG KMT2A 2003/4885MAPT 3428/4885CFD 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.